The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

BACKGROUND: Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. HBI-8000 is a novel, orally bioavai...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissonnette, Reid P., Cesario, Rosemary M., Goodenow, Bob, Shojaei, Farbod, Gillings, Mireille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404302/
https://www.ncbi.nlm.nih.gov/pubmed/34461854
http://dx.doi.org/10.1186/s12885-021-08702-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404302/
https://www.ncbi.nlm.nih.gov/pubmed/34461854
http://dx.doi.org/10.1186/s12885-021-08702-x

Ejemplares similares